Clinical trial

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

NCT00043394

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2002-09-01

PhasePHASE2

Study timeline

Study start (unknown)2002-09-01Date precision: month

Registry last updated2009-03-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Carcinoma, Breastunresolved

Interventions

0.04 mg/kg CpG 7909DRUG

Herceptin®DRUG

0.08 mg/kg CpG 7909DRUG

Herceptin®DRUG

0.12 mg/kg CpG 7909DRUG

Herceptin®DRUG

0.16 mg/kg CpG 7909DRUG

Herceptin®DRUG

Sponsors & collaborators

Pfizerlead sponsor

Mapped research locations

ClevelandOhio, United States1 Washington D.C.District of Columbia, United States1 DetroitMichigan, United States1 Ann ArborMichigan, United States1 New HavenConnecticut, United States1 OrangeCalifornia, United States1 BurlingtonVermont, United States1 PlantationFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00043394 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.